reports
Quadient Strengthens Leadership Position in the 2024 Top 250 Ranking o...
Quadient Strengthens Leadership Position in the 2024 Top 250 Ranking of French Software Companies Quadient secured the 11th position overall and second in the ‘Horizontal Publishers’ category Quadient (Euronext Paris: QDT), a global automation platform powering secure and sustainable business connections, announced today that it has achieved considerable progress in the prestigious Top 250 ranking of French software companies published by EY and Numeum. Quadient advanced to the 11th position in the overall ranking, up from 15th in 2023, and achieved second place in the "Horizontal Publishe...
Information relative au nombre total de droits de vote et d’actions co...
Information relative au nombre total de droits de vote et d’actions composant le capital social Communiqué de Presse Dijon, le 20 novembre 2024 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui développe et commercialisera prochainement un portefeuille de médicaments dédiés aux situations d’urgence, publie conformément aux articles 223-16 du Règlement général de l’AMF et L.233-8 II du Code de commerce, le nombre total de droits de vote et d’actions composant son capital social au 31 octobre 2024. DateNombre d’actions Composant le capitalSocial (1)Nombre de droits d...
- Mahaut Arnaud
- Paul de Froment
- Thomas Mordelle
Lhyfe: partnership with Energy Pool
This morning, Lhyfe announced a demand response partnership with Energy Pool, a leading French flexibility operator and distributed energy services provider with more than 8GW of energy production and storage assets under management worldwide. Leveraging the flexibility of Lhyfe's French PEM electr
Quadient S.A. - Monthly information on number of shares and voting rig...
Quadient S.A. - Monthly information on number of shares and voting rights Monthly information on number of shares and voting rights of Quadient S.A. In accordance with article 223.11 of Autorité des Marchés Financiers’ (French Securities and Investment board) General Regulations Ordinary shares - ISIN: FR0000120560 As at 31 October 2024Total number of shares34,468,912Theoretical total number of voting rights34,468,912Net total number of voting rights33,950,567 For more information, please contact: Catherine Hubert-Dorel, Quadient+33 (0)1 45 36 30 56Caroline Baude, Quadient+33 (0)1 45 36 ...
Crossject’s ZENEO® Auto-Injector's usability further demonstrated in e...
Crossject’s ZENEO® Auto-Injector's usability further demonstrated in extreme HAZMAT conditions Crossject successfully completes a new U.S. summative human factors study to assess the usability of ZENEO® Midazolam, soon to be commercialized globally as ZEPIZURE®, under simulated chemical attack conditions. Rigorous HAZMAT (Hazardous Materials) dry-run involved 75 participants, who deployed 375 ZENEO® Midazolam auto-injectors in challenging conditions, including while wearing protective suits, without any handling problem.Study underscores ZENEO® Midazolam’s usability in extreme, high-ri...
GenSight Biologics Announces Submission of LUMEVOQ® Dossier to ANSM to...
PARIS--(BUSINESS WIRE)-- Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the submission of the updated regulatory file for LUMEVOQ® gene therapy to the French medicines safety agency Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) to prepare for the restart of the early access (AAC) program in France. The submission documents the successful ...
GenSight Biologics annonce la soumission du dossier LUMEVOQ® à l'ANSM ...
PARIS--(BUSINESS WIRE)-- Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible au PEA-PME), société biopharmaceutique spécialisée dans le développement et la commercialisation de thérapies géniques innovantes pour les maladies neurodégénératives rétiniennes et les troubles du système nerveux central, annonce aujourd'hui la soumission du dossier réglementaire actualisé pour la thérapie génique LUMEVOQ® à l'Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) pour préparer la reprise du programme d'accès compassionnel (AAC) en France. Le d...
Quadient S.A. - 2025 Financial Calendar
Quadient S.A. - 2025 Financial Calendar 2025 FINANCIAL CALENDAR Paris, 7 November 2024 Full-year results and Q4 2024 sales: 26 March 2025* Quiet period: from 12 to 26 March 2025 Q1 2025 sales: 3 June 2025* Quiet period: from 20 May to 3 June 2025 Annual General Meeting: 13 June 2025 Half-year results and Q2 2025 sales: 24 September 2025* Quiet period: from 10 to 24 September 2025 Q3 2025 sales: 2 December 2025* Quiet period: from 18 November to 2 December 2025 * Publication after the closing of the Premier Marché of Euronext Paris About Quadient®Quadient is a global automation p...
Quadient S.A. - Calendrier financier 2025
Quadient S.A. - Calendrier financier 2025 CALENDRIER FINANCIER 2025 Paris, le 7 novembre 2024 Résultats annuels et chiffre d'affaires T4 2024 : 26 mars 2025* Période d’embargo : du 12 au 26 mars 2025 Chiffre d'affaires T1 2025 : 3 juin 2025* Période d’embargo : du 20 mai au 3 juin 2025 Assemblée Générale : 13 juin 2025 Résultats semestriels et chiffre d'affaires T2 2025 : 24 septembre 2025* Période d’embargo : du 10 au 24 septembre 2025 Chiffre d'affaires T3 2025 : 2 décembre 2025* Période d’embargo : du 18 novembre au 2 décembre 2025 * Publication après la clôture du Premier Mar...
GenSight Biologics annonce un financement d’un montant d’environ 2,8 m...
PARIS--(BUSINESS WIRE)-- Regulatory News: CE COMMUNIQUE DE PRESSE N'EST PAS DIFFUSE ET DES COPIES NE PEUVENT PAS ETRE DISTRIBUEES OU ENVOYEES, DIRECTEMENT OU INDIRECTEMENT, AUX ETATS-UNIS, AU CANADA, EN AFRIQUE DU SUD, AU JAPON OU EN AUSTRALIE. GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME) (la "Société"), une Société biopharmaceutique spécialisée dans le développement et la commercialisation de thérapies géniques innovantes pour les maladies neurodégénératives de la rétine et les troubles du système nerveux central, a annoncé aujourd'hui un financement par le b...
- Emira Sagaama
- Michael B. Schäfer
SOP SOPRA STERIA GROUP SA
TFI TELEVISION FRANCAISE 1 SA
VETO VETOQUINOL SA
LSS LECTRA SA
EBRO EBRO FOODS SA
MBB MBB INDUSTRIES SE
G24 SCOUT24 AG
ELIS ELIS SA
MAREL MAREL HF.
AIXA AIXTRON SE
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
ROYAL VOPAK NV
DLG DE'LONGHI S.P.A.
FDR FLUIDRA S.A.
MELE MELEXIS NV
SPIE SPIE SA
GLPG GALAPAGOS NV
IDR INDRA SISTEMAS S.A. CLASS A
UNI UNICAJA BANCO S.A.
DUFN DUFRY AG
RUI RUBIS SCA
ALD ALD SA
BFSA BEFESA SA
VOS VOSSLOH AG
WAVE WAVESTONE SA
CLA CLARANOVA SE
ZEL PHARMA MAR SA
AML ASTON MARTIN LAGONDA GLOBAL HOLDINGS
TE TECHNIP ENERGIES NV
FPE3 FUCHS PETROLUB SE
STM STABILUS SE
FLOW FLOW TRADERS LTD
PLX PLUXEE NV
- Emira Sagaama
- Michael B. Schäfer
SOP SOPRA STERIA GROUP SA
TFI TELEVISION FRANCAISE 1 SA
VETO VETOQUINOL SA
LSS LECTRA SA
EBRO EBRO FOODS SA
MBB MBB INDUSTRIES SE
G24 SCOUT24 AG
ELIS ELIS SA
MAREL MAREL HF.
AIXA AIXTRON SE
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
ROYAL VOPAK NV
DLG DE'LONGHI S.P.A.
FDR FLUIDRA S.A.
MELE MELEXIS NV
SPIE SPIE SA
GLPG GALAPAGOS NV
IDR INDRA SISTEMAS S.A. CLASS A
UNI UNICAJA BANCO S.A.
DUFN DUFRY AG
RUI RUBIS SCA
ALD ALD SA
BFSA BEFESA SA
VOS VOSSLOH AG
WAVE WAVESTONE SA
CLA CLARANOVA SE
ZEL PHARMA MAR SA
AML ASTON MARTIN LAGONDA GLOBAL HOLDINGS
TE TECHNIP ENERGIES NV
FPE3 FUCHS PETROLUB SE
STM STABILUS SE
FLOW FLOW TRADERS LTD
PLX PLUXEE NV
- Martin Marandon-Carlhian
- Stephane Houri
AT&S AG : Better-than-expected Q2 sales but disappointing profitabilit...
>Q2 2024-25 results below expectations - AT&S this morning reported its Q2 2024-25 results which beat expectations on sales/adjusted EBITDA but fell short on net profit and operating CF. Sales were € 451m, above the company-compiled consensus at € 423m. They were flat y-o-y and up 29% q-o-q. Adjusted EBITDA was € 127m, i.e. a margin of 28.1%, above the consensus at € 106m and 25%. Net profit was -€ 29m, below the consensus at -€ 10m, due notably to high start-up cos...
- Martin Marandon-Carlhian
- Stephane Houri
AT&S AG : Better-than-expected Q2 sales but disappointing profitabilit...
>Q2 2024-25 results below expectations - AT&S this morning reported its Q2 2024-25 results which beat expectations on sales/adjusted EBITDA but fell short on net profit and operating CF. Sales were € 451m, above the company-compiled consensus at € 423m. They were flat y-o-y and up 29% q-o-q. Adjusted EBITDA was € 127m, i.e. a margin of 28.1%, above the consensus at € 106m and 25%. Net profit was -€ 29m, below the consensus at -€ 10m, due notably to high start-up cos...
EQS-News: AT&S erwartet Umsatz auf Vorjahresniveau
EQS-News: AT&S Austria Technologie & Systemtechnik AG / Schlagwort(e): Halbjahresergebnis/Quartals-/Zwischenmitteilung AT&S erwartet Umsatz auf Vorjahresniveau 31.10.2024 / 07:03 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. AT&S erwartet Umsatz auf Vorjahresniveau Umsatz im 2. Quartal 2024/25 mit 451 Mio. € um 29 % höher als im Vorquartal und auf dem gleichen Niveau wie im Vorjahresquartal (Q2 2023/24: 452 Mio. €; Q1 2024/25: 349 Mio. €) Ausblick für GJ 2024/25 aufgrund der Marktlage angepasst Ausblick für GJ 2026/27 bestä...
EQS-News: AT&S expects revenue at prior-year level
EQS-News: AT&S Austria Technologie & Systemtechnik AG / Key word(s): Half Year Results/Quarterly / Interim Statement AT&S expects revenue at prior-year level 31.10.2024 / 07:03 CET/CEST The issuer is solely responsible for the content of this announcement. AT&S expects revenue at prior-year level Revenue in Q2 2024/25 € 451 million, up 29% on Q1 2024/25 and at the same level as prior-year quarter (Q2 2023/24: € 452 million; Q1 2024/25: € 349 million) Outlook for FY 2024/25 adjusted due to market situation Outlook for FY 2026/27 confirmed Leoben – AT&S expects ...
Quadient secures €25 million Schuldschein facility from EBRD to finan...
Quadient secures €25 million Schuldschein facility from EBRD to finance R&D programs in Czech Republic Quadient secures €25 million Schuldschein facility from EBRD to finance R&D programs in Czech Republic Paris, October 30, 2024 Quadient S.A. (Euronext Paris: QDT), a global automation platform powering secure and sustainable business connections, today announces that it has secured a new €25 million Schuldschein facility from the European Bank of Reconstruction and Development (EBRD) to finance R&D programs in Czech Republic. The Schuldschein loan from the EBRD is for a total nominal...
- Michael B. Schäfer
ODDO BHF Small & MIDCAP MORNING NEWS - 10/29/2024
Temenos, the European leader in core banking solutions with significant market share with Tier 3, 4 and 5 banks, faces structural challenges that impair its growth outlook: 1/ the reticence of major banking groups to renew their core banking system; 2/ fierce competition in the digital segment; and 3/ the slowdown in the launch pace for new neo-banks. Indeed, the group is set to scale back its medium-term targets at its CMD on 12 November. Moreover, the support for the stock offered b...
- Michael B. Schäfer
ODDO BHF S all & MIDCAP MORNING NEWS - 29/10/2024
Temenos, leader européen des solutions Core Banking avec une part de marché significative auprès des banques Tiers 3, 4 et 5, fait face des défis structurels qui réduisent ses perspectives de croissance : 1/ la réticence des grands acteurs bancaires à renouveler leur Core banking system; 2/ la forte compétition sur le segment Digital et 3/ le ralentissement du rythme de lancement de nouvelles néo-banques. Aussi, le groupe devrait abaisser ses objectifs MT lors du CMD du 12 novembre. E...
- Martin Marandon-Carlhian
- Stephane Houri
AT&S AG : New profit warning, raising questions about the investment c...
>Underperformance rating reiterated following a PW raising questions about the investment case and liquidity risk - Target price adjusted to € 15 (vs € 19) - Yesterday, AT&S announced a new profit warning linked to a number of issues (pricing pressure, volatile orders from one customer, weakness of auto/industry, delay in the ramp-up of the AMD fab). We are lowering our EBITDA by ~10% over the next three years and adjusting our target price to €15 (DCF + multiple) vs ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.